Skip to main content
Download PDF

Mycoplasma pneumoniae pneumonia-associated thromboembolism with plastic bronchitis: a series of five case reports and literature review

Italian Journal of Pediatrics volume 50, Article number: 117 (2024) Cite this article

Abstract

Background

Mycoplasma pneumoniae pneumonia is a common respiratory infection among children. However, the occurrence of thromboembolism with plastic bronchitis in association with Mycoplasma pneumoniae pneumonia is extremely rare. This case series presents five cases of children with Mycoplasma pneumoniae pneumonia who developed thromboembolism and plastic bronchitis. The clinical presentation, diagnostic approach, and management strategies are discussed.

Methods

A retrospective analysis was conducted on medical records from a pediatric hospital. Patient demographics, clinical features, laboratory findings, imaging results, treatment modalities, and outcomes were collected.

Results

The patients in our case series presented with varying degrees of respiratory distress, cough, and fever. Imaging studies revealed evidence of thromboembolism based on pulmonary artery occlusion. Bronchial casts were observed by bronchoscopy. Laboratory tests demonstrated elevated D-dimer levels and fibrinogen degradation products. All patients received a combination of low molecular weight heparin anticoagulation and supportive care.

Conclusion

Thromboembolism with plastic bronchitis associated with Mycoplasma pneumoniae pneumonia is a rare but potentially serious complication in children. Prompt recognition and management are crucial for improving patient outcomes. This case series highlights the diverse clinical presentations, diagnostic challenges, and treatment strategies for this unique clinical entity. Further research is needed to better understand the pathogenesis and optimal management of this condition.

Introduction

M. pneumoniae is now recognized as a causative agent of respiratory infections across all age groups and a significant contributor to community-acquired pneumonia [1]. In the United States alone, there are over 2 million cases of Mycoplasma pneumoniae pneumonia (MPP) reported annually, leading to approximately 100,000 hospitalizations each year [2]. In addition to pneumonia, MPP can also give rise to severe extrapulmonary complications such as pleurisy, hydrothorax, plastic bronchitis (PB), embolism, and multiple organ damage [3]. In this study, we first present a series of cases involving children who experienced thromboembolism and plastic bronchitis associated with M. pneumoniae pneumonia. We provide a detailed summary of the clinical findings from five cases demonstrating the presence of embolism and PB in MPP patients.

Methods

Patients and definitions

The inclusion criteria were as follows: ① The condition met the diagnostic criteria for MPP: (i) positive results for the serological test (MP-IgM positive and antibody titer ≥ 1:160); (ii) the positive results for MP polymerase chain reaction (PCR) tests of nasopharyngeal secretions. ② The condition met the diagnostic criteria for thromboembolism: CTA/MRA indicates embolism in the blood vessel or heart. ③ The condition met the diagnostic criteria for PB [4]: (i) expectoration of cohesive bronchial casts which assume the shape of the local airways; (ii) bronchial plastic material can be seen in the extracted or coughed up material under bronchoscopy.

The exclusion criteria were as follows: ① Combined with other pathogenic infections. ② Basic diseases, including chronic cardiopulmonary disease, rheumatism, immune deficiency disease, or severe blood system disease. ③ The age was more than 15 years old. All procedures performed in studies were following the Ethics Committee of Tianjin Children’s Hospital.

Etiological detection

All the children completed the following detection within 24 h of admission: MP-DNA detected by MP polymerase chain reaction (PCR) tests by nasopharyngeal swab, phlegm respiratory pathogen eight (influenza A and influenza B, respiratory syncytial virus, adenovirus, metapneumovirus, parainfluenza virus type 1, 2, 3), blood respiratory pathogen IgM antibody nine (eosinophilic lung Legionella bacteria, Mycoplasma pneumoniae, Chlamydia, Rickettsia, adenovirus pneumonia, respiratory syncytial virus, influenza A virus, influenza B virus, and parainfluenza), tuberculosis and bacterial culture.

Data collection

The clinical data of all children were collected as following: (1) basic information: name, gender, age, BMI, time to CTA/MRA (days), previous venous thrombo embolism (VTE), cardiovascular diseases (CVDs) and ICU admission. (2) clinical manifestations: Tmax, heart rate, main symptoms, distribution of embolism and outcome. (3) laboratory tests: routine blood tests, inflammatory markers, blood biochemistry, autoantibody, coagulation function and humoral immunity. (4) imaging examination results.

Results

Basic information

All five patients included in this study were between the ages of 5 and 9 years old, with a mean age of 6.8 years. Among these cases, three occurred in female patients. The body mass index (BMI) of the patients ranged from 17 to 30.7, with a mean BMI of 16.14. None of the patients had any history of family and basic disease, such as congenital heart disease, metabolic disease, thrombus, cardiovascular surgery, nephrotic syndrome and so on.

Clinical features

All children in this study presented with persistent high fever and cough, accounting for 100% of the cases (n = 5). The maximum recorded temperature during the course of the disease ranged from 40.0 to 40.8 ℃. The duration of the illness before hospitalization at our department ranged from 6 to 12 days, with a mean duration of 8.6 days. Thrombosis occurs between the 13th and 22nd days after the onset of the disease. Notably, only one patient (case 4) experienced chest pain and hemoptysis. Conversely, the primary manifestations in children with cerebral embolism (case 5) included rapid loss of consciousness, limb paralysis, weakness, slurred speech, incomprehensible pronunciation, involuntary movement, and partial eyelid closure, among other symptoms. Unexpectedly, three cases (cases 1, 2, and 3) with pulmonary embolism were asymptomatic, comprising 60% of the cases (n = 3), as shown in Table 1. Additionally, damage to other organs was common, including the heart (n = 2, 40%), liver (n = 2, 40%), and kidneys (n = 5, 100%).

Table 1 The clinical features of pediatric MPP-associated embolism with PB
Full size table

Laboratory examination

MP-DNA replication was detected in the alveolar lavage fluid of all five cases. MP antibodies were found in the blood of four children, with three of them having antibody titers reaching 1:640. The mean levels of D-dimer and fibrinogen (closest to CTA/MRA) were 9.2 ± 2.1 mg/L and 3.8 ± 1.2 g/L, respectively. The peripheral white blood cell (WBC) count of the five children was 12.9 ± 3.1 × 109/L, and the mean neutrophil (N) percentage was 78.5%±7.8%. The mean platelet count was 350.8 ± 70.1 × 109/L, and the average C-reactive protein (CRP) level was 76.3 ± 38.4 mg/L. The mean lactate dehydrogenase (LDH) level was 738.6 ± 122.9 U/L. Elevated erythrocyte sedimentation rate (ESR) levels were detected in four patients. The level of ferritin (FER) was 626.2 ± 396.8 ng/ml, with case 3 reaching as high as 1289 ng/ml, as shown in Table 2. The results of genetic testing for drug resistance in Mycoplasma pneumoniae revealed that cases 2 and 4 exhibited 2063/2064 + drug resistance mutations, while drug resistance testing was not conducted for the remaining three cases. Case 1’s antibody test showed a ANA( +) result with a titer of 1:320 and a granular-type karyotype. In contrast, case 4 tested negative for ACN antibodies. The antibody status of the remaining three cases was undetermined.

Table 2 The laboratory examination of pediatric MPP-associated embolism with PB
Full size table

Radiological examination and bronchoscopy

A pulmonary CT scan revealed pulmonary consolidation (≥ 2/3 lobe) in all cases (n = 5, 100%). However, atelectasis was present in 4 cases (n = 4, 80%), while mild to moderate pleural effusion and pleural thickening were observed in all cases (n = 5, 100%). Case 4 (n = 1, 20%) showed consolidation and necrosis. In the 4 children with pulmonary embolism (n = 4, 80%), the main thromboembolic vessels affected were the bilateral lower lobe pulmonary artery and right upper lobe pulmonary artery (as shown in Table 3). In the case of cerebral embolism (case 5), the primary embolic vessels were the left internal carotid artery and middle cerebral artery. Vascular malformations were not detected in any of the children based on imaging examinations. The average time from onset to bronchoscopy examination was 6–13 days (mean = 9.8 days). Bronchial casts were found in all cases, predominantly in the left lower lobe of the lung (Fig. 1).

Table 3 The radiological examination and bronchoscopy of pediatric MPP-associated embolism with PB
Full size table
Fig. 1
figure 1

The examinations of MPP-associated thromboembolism with PB. (A) (Case 1) The chest CTA revealed filling defects in the bilateral inferior pulmonary arteries. (B) Bronchoscopy unveiled extensive cord-like plugs within the bronchial cavity of the anterior segment of the left upper lobe in Case 1. (C) Fiberoptic bronchoscopy extracted a plastic bronchial tree from the airway. (D) Pathological examination confirmed Type I plastic bronchitis in Case 1. (E) (Case 2) Chest CTA exhibited filling defects in the right lower pulmonary artery. (F) Bronchoscopy disclosed extensive cord-like plugs within the bronchial cavity of the anterior segment of the left upper lobe in Case 2. (G) Fiberoptic bronchoscopy removed a plastic bronchial tree from the airway of Case 2. (H) Pathological findings confirmed Type I plastic bronchitis in Case 2 through Hematoxylin and Eosin (H&E) staining

Full size image

Treatment

All patients received empirical oral antibiotic treatment before admission. After admission, all five patients were administered azithromycin, methylprednisolone (2–10 mg/kg/d), low molecular weight heparin(2 IU/kg/d) for anticoagulation, and aspirin to inhibit platelet aggregation. As shown in, three patients (case2,3,5) also received gammaglobulin treatment. Additionally, the patient with cerebral infarction underwent treatment with a dehydrating agent to reduce intracranial pressure, while those with hepatic injury were administered hepatoprotective drugs. Finally, two patients (case2,5) with massive pleural effusion underwent chest thoracentesis.

Outcome and follow-up

No fatalities were observed during the course of this study, and all cases presenting symptoms associated with thrombosis resolved, with laboratory indexes returning to within the normal range. Their chest X-ray findings approached or returned to normal (Fig. 2). In cases of pulmonary embolism, pulmonary computed tomography angiography (CTA) showed no filling defects after a period of 1–3 months. The child with cerebral embolism was followed up for a period of 12 months. While one of the patients experienced improved limb activity, they still suffered from sequelae including tremors and impaired motor function.

Fig. 2
figure 2

Imaging changes of case 1 and case 2. (A) Case 1: Chest radiography on day 3. (B) Chest radiography on day 6. (C) Chest radiography on day 10. (D) Case 2: Chest radiography on day 1. (E) Chest radiography on day 9. (F) Chest radiography on day 27

Full size image

Discussion

This study conducted a comprehensive search in authoritative databases including PubMed, Embase, and Web of Science by combining subject terms and free words. The subject terms comprised “Mycoplasma Pneumoniae Pneumonia,” “Thromboembolism,” and “Plastic Bronchitis.” Boolean operators “AND” and “OR” were employed to connect related synonyms and expanded vocabularies, such as “Mycoplasma infections” and “Pulmonary embolism,” ensuring the search results’ comprehensiveness and accuracy.

Previous reports have indicated that thrombosis or plastic bronchitis can manifest independently following Mycoplasma pneumoniae infection. Instances of severe Mycoplasma pneumoniae pneumonia accompanied by thrombosis and plastic bronchitis are not uncommon. Therefore, after excluding articles with incomplete data and cases of mixed infection, this paper focuses on eight relevant articles. Early detection and proactive interventions such as thrombolysis, anticoagulation, and bronchoscopy treatments often lead to improved prognoses shown in Table 4.

However, detailed case reports regarding thrombosis and plastic bronchitis resulting from Mycoplasma pneumoniae infection are lacking. Similarly, the mechanisms underlying Mycoplasma pneumoniae-induced thrombosis and plastic bronchitis remain unexplored. Although Liu J’s report mentioned four concurrent cases, no detailed introduction or summary was provided. This suggests that while cases of simultaneous thrombosis and plastic bronchitis may have occurred previously, they have not been thoroughly understood or documented. This paper presents five cases of concurrent thrombosis and plastic bronchitis, aiming to elucidate the underlying mechanisms and enhance understanding of these related conditions.

Table 4 The therapy regimens and outcome of the literature review of the MPP-associated thromboembolism with PB
Full size table

Mycoplasma pneumoniae has been shown to directly or indirectly [3] induce airway inflammation by recruiting a substantial number of inflammatory cells and mediators, such as TNF-α, IL-1β, H2O2, and hypoxia-inducible factor [13]. These factors are known to lead to the structural damage to lymphatic vessels in the lungs [14]. Consequently, the disrupted structure of pulmonary lymphatic vessels compromises their ability to efficiently absorb inflammation [15] and regulate immune responses [16]. As a result, the accumulation of pleural effusion or pleurisy occurs [17], as observed in the cases presented in this study. Furthermore, Mycoplasma pneumoniae significantly stimulates the VEGF-C/VEGFR-3 signaling pathway, leading to lymphatic vessel hyperplasia [18]. This hyperplasia can establish a direct connection between the channels of pulmonary vein circulation. The leakage of lymph from damaged lymphatic vessels, along with the presence of inflammatory cells in the trachea, contributes to the development of type I plastic bronchitis, which is similar to the outcomes of Fontan surgery [19, 20]. Leaked lymph increases blood viscosity, damages blood vessel walls, and disrupts the balance of the fibrinolytic coagulation system, ultimately leading to the formation of blood clots. This may explain the higher susceptibility of pulmonary blood vessels to thromboembolism [21, 22], which is supported by the fact that four out of five thrombosis sites in our cases were observed in the lungs as shown in Fig. 3.

Fig. 3
figure 3

MPP-associated thromboembolism with PB mechanism diagram

Full size image

After an average time from onset of 6–13 days (mean = 9.8 days), imaging findings in patients demonstrated atelectasis and extensive pulmonary inflammation and consolidation. Bronchoscopy plays a crucial role in both diagnosing [23] and treating pulmonary inflammation and pulmonary ventilation dysfunction [24]. Following the criteria set by Wang L’s team, we conducted fiberoptic bronchoscopy and alveolar lavage fluid examination [25]. Fiberoptic bronchoscopy identified multiple plastic tracheal obstructions, which were successfully removed using forceps followed by alveolar lavage. Pathological analysis confirmed that the removed plastic substance was consistent with type I plastic bronchitis. Despite the alleviation of airway obstruction and identification of the pathogen, the consolidation area in the lungs did not show significant improvement on chest X-ray. Managing plastic bronchitis is a challenging task, often requiring repeated bronchoscopy for cast removal [26]. Subsequent bronchoscopy examination revealed a significant amount of mucus plugs in the trachea, which were cleared, resulting in improvement on chest X-ray.

After an average duration of 13–22 days from the onset of symptoms (mean = 16 days), the children’s blood oxygen saturation remained below normal levels. Given the elevation of D-dimer levels and the possibility of pulmonary embolism [27], the children underwent a CTA examination, which confirmed the presence of pulmonary embolism in 4 cases. In three of these cases, the emboli were located in the right lower pulmonary artery, while in 1 case, both lower pulmonary arteries were affected. It is noteworthy that only one case (case 4) presented with symptoms of chest pain and hemoptysis, while the remaining cases were asymptomatic. In case 5, typical symptoms of cerebral embolism were observed, including right hemiplegia, dysarthria, and cognitive impairment. Urgent MRA was performed, revealing interruption of blood flow in the left internal carotid artery and middle cerebral artery, thus confirming the diagnosis of cerebral embolism.

Hormonal therapy, in conjunction with appropriate antimicrobial agents, has demonstrated promising outcomes in the management of refractory MPP [1]. In our treatment regimen, azithromycin was included based on the literature indicating potential immunomodulatory and anti-inflammatory effects, even in the presence of drug resistance [28]. Notably, corticosteroids have been proven to effectively suppress inflammation and offer a cost-effective solution. In our previous investigations [29], early administration of high-dose corticosteroid pulse therapy for patients with refractory Mycoplasma pneumoniae pneumonia presenting with elevated laboratory inflammatory markers and pleural effusion was shown to be advantageous in controlling the patient’s condition and prognosis. Following hormone therapy in all five cases, a rapid interruption of the inflammatory storm and swift normalization of body temperature was observed within a few days. Subsequently, we gradually and steadily reduced the hormone dosage, and importantly, no recurrence of the patient’s condition was observed thereafter. These findings suggest that a more cautious approach to the utilization of corticosteroid hormones may be warranted for similar patients.

Currently, the treatment of thrombosis consists of anticoagulant therapy, thrombolytic therapy, and surgical thrombectomy [30]. However, the management of MPP complicated with thrombosis is relatively rare and lacks a standardized approach. Drawing from the American Guidelines for the Treatment of Thrombosis in Children [31] and our team’s previous experience in managing MPP thrombosis [7], we devised a conservative management protocol that involves using low molecular weight heparin (LMWH) for anticoagulation at a dosage of 2 IU/kg/day while regularly monitoring levels of D-dimer and fibrinogen (Fg). It is important to note that relying solely on D-dimer measurement to exclude pulmonary embolism may lead to the oversight of smaller subsegmental emboli [32]. Therefore, we incorporated Fg as an additional marker to more accurately assess the body’s coagulation status. LMWH has demonstrated effectiveness, safety, and good tolerability in children, thereby reducing the risk of pulmonary necrosis [33]. However, in cases where patients present with cardiovascular or cerebrovascular embolism or experience hemodynamic changes, we employ thrombolytic therapy (case 5).

Nonetheless, it is regrettable that several limitations persist, notably a restricted sample size. Moreover, there are instances of incomplete clinical data and laboratory examinations for patients. Thirdly, it is imperative to conduct further exploration into the specific mechanisms responsible for complications related to thrombosis and pulmonary embolism induced by MPP.

Conclusion

Thromboembolism with plastic bronchitis associated with Mycoplasma pneumoniae pneumonia is a rare but potentially serious complication in children. Prompt recognition and management are crucial for improving patient outcomes. This case series highlights the diverse clinical presentations, diagnostic challenges, and treatment strategies for this unique clinical entity. Further research is needed to better understand the pathogenesis and optimal management of this condition.

Data availability

The datasets generated and/or analyzed during the current study are available from our manuscript.

Abbreviations

LMWH:

Low molecular weight heparin

MPP:

Mycoplasma pneumoniae pneumonia

PB:

Plastic bronchitis

References

  1. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747–809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Alvaro Varela AI, Aguinaga Perez A, Navascues Ortega A, Castilla Catalan J, Ezpeleta Baquedano C. [Macrolide-resistant Mycoplasma pneumoniae: do we know the situation in Europe?]. Rev Esp Quimioter. 2023;36(3):259–66.

    Article  CAS  PubMed  Google Scholar 

  3. Narita M. Classification of Extrapulmonary manifestations due to mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ntiamoah P, Mukhopadhyay S, Ghosh S, Mehta AC. Recycling plastic: diagnosis and management of plastic bronchitis among adults. Eur Respir Rev 2021;30(161).

  5. Chen L, Yin J, Liu X, Liu J, Xu B, Shen K. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children. Clin Respir J. 2023;17(3):187–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim YS, Lee YY, Lee E. Cases of macrolide-resistant Mycoplasma pneumoniae pneumonia-associated pulmonary thromboembolism. Pediatr Pulmonol. 2021;56(6):1796–9.

    Article  PubMed  Google Scholar 

  7. Zhang T, Zheng J, Wang H, Xu Y, Ning J, Cai C. Case Report: Cardiac multiple Thrombus and pulmonary embolism associated with mycoplasma pneumonia infection in a child. Front Pediatr. 2022;10:959218.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Liu J, He R, Wu R et al. Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing children’s hospital. BMC Infect Dis 2020;20(1).

  9. Sheng CQ, Yang CF, Ao Y, Zhao ZY, Li YM. Mycoplasma pneumoniae pneumonia with pulmonary embolism: a study on pediatric cases in Jilin Province of China. Exp Ther Med. 2021;21(3):201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang L, Zhang Y, Shen C, et al. Clinical features and risk factors of plastic bronchitis caused by Mycoplasma pneumoniae pneumonia in children. BMC Pulm Med. 2023;23(1):468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang H, Yang J, Zhao W, et al. Clinical features and risk factors of plastic bronchitis caused by refractory Mycoplasma pneumoniae pneumonia in children: a practical nomogram prediction model. Eur J Pediatr. 2023;182(3):1239–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhang T, Han C, Guo W, Ning J, Cai C, Xu Y. Case report: clinical analysis of fulminant mycoplasma pneumoniae pneumonia in children. Front Pediatr. 2021;9:741663.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shankar N, Thapa S, Shrestha AK et al. Hyperoxia disrupts lung lymphatic homeostasis in neonatal mice. Antioxid (Basel) 2023;12(3).

  15. Baluk P, Adams A, Phillips K, et al. Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation. Am J Pathol. 2014;184(5):1577–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ma Y, Yang X, Chatterjee V, Wu MH, Yuan SY. The gut-lung axis in systemic inflammation. Role of mesenteric lymph as a conduit. Am J Respir Cell Mol Biol. 2021;64(1):19–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Expert Panel on Vascular I, Interventional R, Majdalany BS, et al. ACR appropriateness criteria((R)) chylothorax treatment planning. J Am Coll Radiol. 2017;14(5S):S118–26.

    Google Scholar 

  18. Schwager S, Detmar M. Inflammation and lymphatic function. Front Immunol. 2019;10:308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Do P, Randhawa I, Chin T, Parsapour K, Nussbaum E. Successful management of plastic bronchitis in a child post Fontan: case report and literature review. Lung. 2012;190(4):463–8.

    Article  PubMed  Google Scholar 

  20. Languepin J, Scheinmann P, Mahut B, et al. Bronchial casts in children with cardiopathies: the role of pulmonary lymphatic abnormalities. Pediatr Pulmonol. 1999;28(5):329–36.

    Article  CAS  PubMed  Google Scholar 

  21. Kirschen MP, Dori Y, Itkin M, Licht DJ, Ichord R, Vossough A. Cerebral lipiodol embolism after lymphatic embolization for plastic bronchitis. J Pediatr. 2016;176:200–3.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Flateau C, Asfalou I, Deman AL, et al. Aortic thrombus and multiple embolisms during a mycoplasma pneumoniae infection. Infection. 2013;41(4):867–73.

    Article  CAS  PubMed  Google Scholar 

  23. Sachdev A, Chhawchharia R. Flexible fiberoptic bronchoscopy in pediatric practice. Indian Pediatr. 2019;56(7):587–93.

    Article  PubMed  Google Scholar 

  24. Criner GJ, Eberhardt R, Fernandez-Bussy S, et al. Interventional bronchoscopy. Am J Respir Crit Care Med. 2020;202(1):29–50.

    Article  PubMed  Google Scholar 

  25. Wang L, Xie Q, Xu S, et al. The role of flexible bronchoscopy in children with mycoplasma pneumoniae pneumonia. Pediatr Res. 2023;93(1):198–206.

    Article  CAS  PubMed  Google Scholar 

  26. Eber E, Antón-Pacheco JL, de Blic J et al. ERS statement: interventional bronchoscopy in children. Eur Respir J 2017;50(6).

  27. Rohacek M, Buatsi J, Fau - Szucs-Farkas Z, Szucs-Farkas Z, Fau - Kleim B, et al. Ordering CT pulmonary angiography to exclude pulmonary embolism: defense versus evidence in the emergency room. Intensive Care Med. 2012;38(8):1345–51.

    Article  PubMed  Google Scholar 

  28. Heidary M, Ebrahimi Samangani A, Kargari A, et al. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal. 2022;36(6):e24427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhu Z, Zhang T, Guo W, Ling Y, Tian J, Xu Y. Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy. BMC Infect Dis. 2021;21(1):126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Korte W, Cattaneo M, Fau - Chassot PG, Chassot Pg Fau - Eichinger S, the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH). Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of, the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost. 2011;105(5):743–749.

  31. Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292–316.

    Article  PubMed  PubMed Central  Google Scholar 

  32. De Monyé W, Sanson BJ, Mac Gillavry MR, et al. Embolus location affects the sensitivity of a rapid quantitative D-dimer assay in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 2002;165(3):345–8.

    Article  PubMed  Google Scholar 

  33. Zheng B, Zhao J, Cao L. The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children. BMC Infect Dis. 2020;20(1):391.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We owe our thanks to all the medical staffs for their work on revising and data extracting in this manuscript.

Funding

This work was supported by Tianjin Natural Science Foundation [Grant number 21JCYBJC00460]. We are grateful for the financial support funded by the Program of Tianjin Children’s Hospital High-Level Talent Technology Improvement and Training. We are grateful for the financial support funded by the Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-040A).

Author information

Author notes

  1. Peng Jin and Chunjiao Han contributed equally to this work.

Authors and Affiliations

  1. Department of Respiratory Medicine, Tianjin University Children’s Hospital (Tianjin Children’s Hospital), 238 Longyan Road, Beichen District, Tianjin, 300134, China

    Peng Jin, Chunjiao Han, Wei Guo & Yongsheng Xu

  2. Clinical School of Pediatrics, Tianjin Medical University, Tianjin, China

    Peng Jin & Chunjiao Han

Authors
  1. Peng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunjiao Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yongsheng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PJ and CH contributed to the conception of the study. PJ and CH contributed significantly to analysis and manuscript preparation. PJ performed the data analyses and wrote the manuscript. WG and YX helped perform the analysis with constructive discussions. All authors contributed to the article and approved the final manuscript.

Corresponding authors

Correspondence to Wei Guo or Yongsheng Xu.

Ethics declarations

Ethics approval and consent to participate

This report was approved by the Ethics Committee of the Children’s Hospital of Tianjin (Children’s Hospital of Tianjin University), in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consents were obtained from the parents for publication of this report.

Consent for publication

Written informed consents were obtained from the patients for publication of this article and accompanying images.

Competing interests

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, P., Han, C., Guo, W. et al. Mycoplasma pneumoniae pneumonia-associated thromboembolism with plastic bronchitis: a series of five case reports and literature review. Ital J Pediatr 50, 117 (2024). https://doi.org/10.1186/s13052-024-01690-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13052-024-01690-1

Keywords

Italian Journal of Pediatrics

ISSN: 1824-7288

Contact us